GR3033005T3 - Application of riluzole in the treatment of mitochondrial diseases - Google Patents

Application of riluzole in the treatment of mitochondrial diseases

Info

Publication number
GR3033005T3
GR3033005T3 GR990403136T GR990403136T GR3033005T3 GR 3033005 T3 GR3033005 T3 GR 3033005T3 GR 990403136 T GR990403136 T GR 990403136T GR 990403136 T GR990403136 T GR 990403136T GR 3033005 T3 GR3033005 T3 GR 3033005T3
Authority
GR
Greece
Prior art keywords
treatment
pct
riluzole
mitochondrial diseases
application
Prior art date
Application number
GR990403136T
Other languages
English (en)
Inventor
Jean-Christophe Delumeau
Michel Martinet
Michel Reibaud
Jean-Marie Stutzmann
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of GR3033005T3 publication Critical patent/GR3033005T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GR990403136T 1994-01-12 2000-04-06 Application of riluzole in the treatment of mitochondrial diseases GR3033005T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9400249A FR2714828B1 (fr) 1994-01-12 1994-01-12 Application du riluzole dans le traitement des maladies mitochondriales.
PCT/FR1995/000023 WO1995019170A1 (fr) 1994-01-12 1995-01-09 Application du riluzole dans le traitement des maladies mitochondriales

Publications (1)

Publication Number Publication Date
GR3033005T3 true GR3033005T3 (en) 2000-07-31

Family

ID=9458947

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990403136T GR3033005T3 (en) 1994-01-12 2000-04-06 Application of riluzole in the treatment of mitochondrial diseases

Country Status (14)

Country Link
US (1) US5686475A (el)
EP (1) EP0738147B1 (el)
JP (1) JP3585045B2 (el)
AT (1) ATE191342T1 (el)
AU (1) AU1458495A (el)
DE (1) DE69516110T2 (el)
DK (1) DK0738147T3 (el)
ES (1) ES2145902T3 (el)
FR (1) FR2714828B1 (el)
GR (1) GR3033005T3 (el)
IL (1) IL112288A (el)
PT (1) PT738147E (el)
WO (1) WO1995019170A1 (el)
ZA (1) ZA95150B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000048847A (ko) 1996-10-01 2000-07-25 스즈키 다다시 미토콘드리아 막 안정화제
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6239156B1 (en) * 1999-04-29 2001-05-29 Centre National De La Recherche Scientifique Cnrs Method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
JP2004531691A (ja) 2000-11-22 2004-10-14 アラーガン、インコーポレイテッド 一過性ナトリウムチャネルと持続性ナトリウムチャネルとを選択的に識別するチャネル遮断薬を同定するためのハイスループットスクリーン
US6479458B1 (en) 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US9629817B2 (en) 2005-08-25 2017-04-25 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
EP2243476A1 (en) * 2009-04-17 2010-10-27 Centre National de la Recherche Scientifique Compounds for the treatment of mitochondrial diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
ES2043070T3 (es) * 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
AU1458495A (en) 1995-08-01
JP3585045B2 (ja) 2004-11-04
IL112288A (en) 1999-04-11
US5686475A (en) 1997-11-11
DK0738147T3 (da) 2000-07-10
JPH09507498A (ja) 1997-07-29
EP0738147B1 (fr) 2000-04-05
ZA95150B (en) 1995-09-07
DE69516110D1 (de) 2000-05-11
FR2714828A1 (fr) 1995-07-13
WO1995019170A1 (fr) 1995-07-20
ES2145902T3 (es) 2000-07-16
EP0738147A1 (fr) 1996-10-23
DE69516110T2 (de) 2000-09-28
ATE191342T1 (de) 2000-04-15
PT738147E (pt) 2000-08-31
IL112288A0 (en) 1995-03-30
FR2714828B1 (fr) 1996-02-02

Similar Documents

Publication Publication Date Title
ZA913282B (en) Dosage form
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
GB2284351B (en) Terfenadine metabolites and their optically pure isomers for treating allergic disorders
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ZA95150B (en) Application of riluzole in the treatment of mitochondrial diseases
PL320687A1 (en) Use of incense for treating alzheimer disease
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
MY124465A (en) Reduction of infarct volume using citicoline
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
GB9421472D0 (en) Novel methods
NZ299257A (en) Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
GB9216859D0 (en) Medicaments
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
GR3022608T3 (en) USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE.
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
SE9101341D0 (sv) New medicinal use
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят
UA22090A (uk) Спосіб лікуваhhя раhової хвороби